Wednesday, January 2, 2013

2012's top stories in biotechnology

Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eeaNCduTtWCfoOhyCidncVCicNaqmN

January 2, 2013
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
  • 2012's top stories in biotechnology
    Genetic Engineering & Biotechnology News lists nine of the most important developments in the biotech industry for 2012. Among the stories for the year was the FDA's issuance in February of a draft guidance for the development and approval of biosimilar drugs. The threat of cuts as part of the "fiscal cliff" loomed over the budgets of the NIH, FDA, CDC and National Science Foundation. The year ended without a blockbuster merger or acquisition but with more new drug approvals from the FDA than 2011. Genetic Engineering & Biotechnology News (12/31) LinkedInFacebookTwitterEmail this Story
  Health Care & Policy 
  • J&J's tuberculosis drug Sirturo wins FDA approval
    The FDA approved the use of Johnson & Johnson's Sirturo, or bedaquiline, in combination with other drugs, to treat patients with multidrug-resistant tuberculosis. Sirturo, developed by J&J's Janssen Therapeutics, is the first new tuberculosis drug to gain approval in 40 years. Because of the possibility of fatal heart problems, Sirturo will carry a boxed warning. Reuters (12/31), MSN/The Associated Press (1/1) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  • Ignyta closes Series B funding round with additional $5.5M
    Ignyta raised an additional $5.5 million in a Series B financing round, bringing its total funds raised in the round to $6 million. The company will use the money to launch clinical trials of its molecular-based diagnostic test for rheumatoid arthritis, and seek CLIA certification to support a launch late next year or in early 2015. Xconomy/San Diego (12/31) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Researchers tweak xylan, lignin for cellulosic biofuel production
    Researchers at the Joint BioEnergy Institute are genetically modifying the xylan and lignin in selected plants to make crops that are easier to process for cellulosic biofuel production, according to studies published in Plant Biotechnology Journal and Biotechnology for Biofuels. The researchers found ways to limit the xylan and lignin content without impeding plant growth, the studies showed. "We got the idea to try to remove lignin or xylan from all the other cell types, but not from the vessels," said Henrik Scheller, vice president of JBEI's feedstocks division. EthanolProducer.com (12/28) LinkedInFacebookTwitterEmail this Story
  • Indian state aims to make ethanol from cashew, coffee pulp
    The Karnataka State Biofuel Development Board in India is planning to establish pilot plants for the production of ethanol from cashew apple and coffee pulp, said Y.B. Ramakrishna, the board's executive chairman, at the opening of the Dakshina Kannada biofuel information and demonstration facility. Concerns about state tax rules must be addressed before the plan can proceed, said A.K. Monnappa, the board's managing director. The Hindu (India) (12/30) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
Birds sing after a storm; why shouldn't people feel as free to delight in whatever remains to them."
--Rose Kennedy,
American philanthropist


LinkedInFacebookTwitterEmail this Story

 
 
This SmartBrief was created for jmabs1@gmail.com
 
Subscriber Tools
     
Update account information | Change e-mail address | Unsubscribe | Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information

No comments: